Treatment for Elderly AML Patients with Multiple Comorbidities

Introduction to Treatment Guidelines

The National Comprehensive Cancer Network recommends venetoclax combined with a hypomethylating agent (azacitidine or decitabine) as first-line therapy for elderly AML patients with significant comorbidities, such as CKD stage 3, heart failure, hypertension, and diabetes, who are not candidates for intensive chemotherapy 1, 2.

Patients are considered unfit for intensive chemotherapy if they are aged ≥75 years (or ≥65 with significant comorbidities), have CKD stage 3, heart failure, or multiple comorbidities, and should receive low-intensity therapy instead 1, 2, 3, 4.

The combination of venetoclax with either azacitidine or decitabine is FDA-approved and represents the current standard for elderly patients with comorbidities precluding intensive chemotherapy, with a recommended venetoclax dose of 400 mg orally daily and azacitidine dose of 75 mg/m² subcutaneously or IV for 7 days every 28 days 1, 2, 5.
The expected outcomes with venetoclax + HMA include a CR/CRi rate of 67% overall, a median overall survival of 17.5 months, and a median duration of remission of 11.3 months 2.

If venetoclax is unavailable or contraindicated, alternative options include HMA monotherapy (azacitidine or decitabine), low-dose cytarabine, or glasdegib + low-dose cytarabine, with response rates and median overall survival varying depending on the regimen 1, 2, 6, 7, 8.

Renal function monitoring is crucial, with CKD stage 3 requiring dose adjustments for certain agents and avoidance of clofarabine entirely 3.
Cardiac monitoring is also essential, with heart failure requiring careful fluid management during HMA administration and monitoring for anthracycline-related cardiotoxicity if any prior exposure 1, 3.
Diabetes management is important, with corticosteroids complicating glucose control and HMAs not significantly affecting glucose metabolism 6, 7, 9.

Transfusion support, infection prophylaxis, and tumor lysis syndrome prevention are critical components of supportive care, with febrile neutropenia occurring in 30-61% of patients on venetoclax + HMA and infections (any grade) occurring in 84% of patients 5.

Best supportive care alone should not be used when low-intensity therapy is feasible, and therapy should not be discontinued prematurely, as 79.7% of untreated elderly AML patients die within 60 days 1, 2.
Standard-dose intensive chemotherapy should not be used in patients with CKD stage 3, heart failure, and advanced age, and lack of response after 1-2 cycles should not lead to discontinuation of therapy, as HMAs require active DNA replication and responses emerge over multiple cycles 3, 1.